Educational resources

Celltrion supplement cover

Switching from intravenous to subcutaneous infliximab biosimilar (Remsima®) in adult patients with inflammatory bowel disease: experience at an NHS trust

Commissioned by Celltrion Healthcare UK Ltd

This supplement has been commissioned and funded by Celltrion Healthcare UK Ltd and developed in partnership with Guidelines in Practice.
View prescribing information

PEI checklist

Implementing the clinical guideline on pancreatic exocrine insufficiency in diabetes

Supported by an educational grant from Mylan

Information intended for healthcare professionals only.